|
KMID : 1040620160220010152
|
|
Clinical and Molecular Hepatology
2016 Volume.22 No. 1 p.152 ~ p.159
|
|
|
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
|
|
Park Chan-Ho
Jung Seok-Won
Shin Jung-Woo
Bae Mi-Ae
Lee Yoon-Im
Park Yong-Tae
Chung Hwa-Sik
Park Neung-Hwa
|
|
|
Abstract
|
|
|
Background/Aims: Tenofovir disoproxil fumarate (TDF) exhibits similar antiviral efficacy against treatment-naive and lamivudine (LAM)-resistant chronic hepatitis B (CHB). However, there are few clinical reports on the antiviral effects of TDF?LAM combination therapy compared to TDF monotherapy in patients with LAM-resistant CHB.
Methods: We investigated the antiviral efficacy of TDF monotherapy vs. TDF?LAM combination therapy in 103 patients with LAM-resistant CHB.
Results: The study subjects were treated with TDF alone (n=40) or TDF?LAM combination therapy (n=63) for ≥6 months. The patients had previously been treated with TDF-based rescue therapy for a median of 30.0 months (range, 8?36 months). A virologic response (VR) was achieved in 99 patients (96.1%): 95.0% (38/40) of patients in the TDF monotherapy group and 96.8% (61/63) of patients in the TDF?LAM combination therapy group. The VR rates were not significantly different between the TDF monotherapy and TDF?LAM combination therapy groups (88.9 vs. 87.3% at month 12, and 94.4 vs. 93.7% at month 24, log-rank p=0.652). Univariate and multivariate analyses revealed that none of the pretreatment factors were significantly associated with VR.
Conclusions: TDF monotherapy was as effective as TDF?LAM combination therapy for maintaining viral suppression in the vast majority of patients with LAM-resistant CHB, which suggests that TDF add-on therapy with LAM is unnecessary.
|
|
|
KEYWORD
|
|
|
Tenofovir, Lamivudine, Resistance, Chronic hepatitis B
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|